Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 1

OncLive

The FDA has approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies.